Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M
January 23, 2026 17:00 ET | Source: Corvus Pharmaceuticals, Inc. SOUTH SAN…
Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Company to host conference call and webcast on Tuesday, January 20, 2026…
